SFLLRNPNDKYEPF是一种人工合成的凝血酶受体激动剂肽段‌，其详细信息如下： 综上所述，SFLLRNPNDKYEPF是一种重要的科研试剂，在凝血机制研究和细胞 ...

Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for ...

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...

Direct inhibition of thrombin may offer similar anticoagulant properties but also impact the underlying disease process. As we continue to gain experience and develop new DTIs, a new balance may ...

Antithrombin, a plasma protein, has been reported to control thrombin activity by directly binding to thrombin, as well as to have an anti-inflammatory effect. However, the actual molecular ...